Evidence map›Paper›PMID 28900714›Full record

ArticleWiener klinische Wochenschrift2018

Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.

Michael Gschwantler, Hermann Laferl, Wolfgang Vogel, Wolfgang Korak, Stephan Moser, Harald Hofer, Bernhard Bauer, Michael Schleicher, Barbara Bognar, Martin Bischof and 4 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01416610 (A Prospective, Observational, Multicenter Non-interventional Trial Examining Efficacy of Combination Therapy With PEGASYS®), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01416610 completednot on this map

A Prospective, Observational, Multicenter Non-interventional Trial Examining Efficacy of Combination Therapy With PEGASYS® (Peginterferon Alfa-2a 40KD) Plus COPEGUS® (Ribavirin) in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing an Opioid Maintenance-Therapy With Special Focus on Patient Compliance and Quality of Life

TypeobservationalSponsorHoffmann-La RocheRan2010 to 2014Enrolled88ConditionsHepatitis C, Chronic
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Michael GschwantlerDepartment of Internal Medicine IV, Wilhelminenspital, Montleartstrasse 37, 1160, Vienna, Austria. michael.gschwantler@wienkav.at.
Hermann LaferlDepartment of Internal Medicine IV, Kaiser-Franz-Josef-Spital, Vienna, Austria.
Wolfgang VogelDepartment of Medicine II, Gastroenterology and Hepatology, Medical University of Innsbruck, Innsbruck, Austria.
Wolfgang KorakDepartment of Internal Medicine I, Klinikum Klagenfurt, Klagenfurt, Austria.
Stephan MoserDepartment of Internal Medicine IV, Wilhelminenspital, Montleartstrasse 37, 1160, Vienna, Austria.
Harald HoferDepartment of Internal Medicine III, Medical University, Vienna, Austria.
Bernhard BauerDepartment of Internal Medicine, LKH Hörgas, Hörgas, Austria.
Michael SchleicherDepartment of Internal Medicine IV, Wilhelminenspital, Montleartstrasse 37, 1160, Vienna, Austria.
Barbara BognarGesundheitszentrum Wien-Mitte, Vienna, Austria.
Martin BischofDepartment of Internal Medicine IV, KA Rudolfstiftung, Vienna, Austria.
Rudolf StauberDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Andreas MaieronDivision of Gastroenterology and Hepatology, Internal Medicine IV, Elisabeth Hospital Linz, Linz, Austria.
Peter FerenciDepartment of Internal Medicine III, Medical University, Vienna, Austria.
Austrian Hepatitis Study Group
Wilhelminen Hospital · ATInnsbruck Medical University · ATMedical University of Graz · ATMedical University of Vienna · ATKlinikum Klagenfurt · ATKrankenanstalt Rudolfstiftung der Stadt Wien · ATKrankenhaus der Elisabethinen · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with a history of intravenous drug abuse included in an official opioid substitution program represent an important subgroup of patients with chronic hepatitis C. The objective of this study was to assess the efficacy of and adherence to treatment with peginterferon and ribavirin in Austrian patients on stable opioid substitution therapy (OST).

methodsThis prospective, multicenter, observational, non-interventional trial (clinicaltrials.gov identifier, NCT01416610) included treatment-naïve patients with chronic hepatitis C on OST. Treatment consisted of peginterferon alpha-2a (PEGASYS®, 180 µg/week) plus ribavirin (COPEGUS®, 1000/1200 mg/day in genotypes (GT) 1/4 and 800 mg/day in GT 2/3) for 24-72 weeks, according to GT and viral response.

resultsThe intention-to-treat (ITT) population comprised 88 patients. Mean duration of therapy was 6.0 ± 2.8 months. Treatment was discontinued earlier than planned in 34 out of 88 patients (39%), mainly because of poor adherence or side effects of treatment. At the end of treatment 65/88 patients (74%) were PCR negative. During follow-up, 5 patients relapsed. Only 44/88 patients (50%) could be evaluated 24 weeks after the end of treatment. Sustained virologic response 24 weeks after end of therapy (SVR24) was documented in 39/88 patients (44%). If only patients were considered who finished treatment as planned and for whom results at follow-up week 24 were available, the SVR24 rate was 89% (32/36).

conclusionDespite favorable prognostic factors, such as young age and a high proportion of GT3, SVR rates were low in this cohort of patients receiving OST, the main reason being poor adherence; however, in those patients completing treatment, the SVR rate was high.

Indexed as

Antiviral AgentsOpiate Substitution TreatmentAdultAustriaDrug Therapy, CombinationFemaleGenotypeHumansInterferon-alphaMalePolyethylene GlycolsProspective StudiesQuality of LifeRecombinant ProteinsRibavirinTreatment OutcomeAntiviral AgentsInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRibavirinChronic hepatitis CPeginterferonPeople who inject drugs (PWID)Ribavirin

Identifiers

PMID28900714
OpenAlexW2755965156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.